Building a future where no one dies from skin cancer.

Skin Analytics delivers world-leading skin cancer pathways through our clinically proven AI technology.

We partner with health systems to improve diagnostic capacity and ensure every patient receives the right care at the right time

Waitlist Management & Clinical Capacity

Safely discharge 30–55% of benign cases at the point of referral.

Clinical Risk Stratification

With a 99.9% Negative Predictive Value for melanoma, our digital triage assistant provides a permanent safety net for your routine list, ensuring no urgent case is left waiting in the backlog. The world’s only Class III CE-marked AI for skin cancer.

Sustainability: Future-Proofing the Pathway

Move beyond short-term fixes toward a scalable, tech-enabled model. Aligned with Sláintecare’s “Right Care, Right Place” mandate.

DERM Pathway:

The world’s only Class III CE-marked AI for skin cancer.

lesions assessed as ‘high-risk’ by DERM are:

20-40%

patients typically discharged

47%

increase in dermatologist-reviewed cases confirmed as malignant

2x

more likely to be routed to biopsy or excision

DERM Performance

DERM performs at least as well as a face-to-face dermatologist.

99.8%

Dermatologist

99.9%

DERM

Negative Predictive Value (Melanoma)

Interested?

Contact our team to find out more